Scientists believe they could be on the cusp of a breakthrough, after a drugs company said it had the first treatment of its kind for Alzheimer’s.
Biogen says it will soon seek regulatory approval in the US for the “groundbreaking” drug, called aducanumab.
It plans to file the paperwork in early 2020 and has its sights on Europe too.
The drug, which is called aducanumab, cannot cure it but Biogen says it slows down the rate at which it progresses, essentially meaning people stay more like themselves for longer.
This came as a surprise as the company had suspended the drug trial in March 2019 because of disappointing results.
But now a larger dataset has been analysed and Biogen says it shows that higher doses of aducanumab can provide a significant benefit to patients with early Alzheimer’s.
Via BBC
